Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SHBG | P04278 | 1/20 | 0.44 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | IAPP | P10997 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660344 | 0.85 | IAPP (0.46) | PRKCIIAPP | |
| SCHEMBL10863076 | 0.84 | SMN1; SMN2 (0.37) | TYRMEN1KMT2AMAPTPRKCI | |
| SCHEMBL9130849 | 0.83 | IAPP (0.44) | PRKCIIAPP | |
| SCHEMBL6244752 | 0.81 | TYR (0.46) | TYRMEN1KMT2AMAPTSHBG | |
| SCHEMBL6248841 | 0.81 | TYR (0.50) | TYRMEN1KMT2AMAPTSHBG | |
| SCHEMBL28606012 | 0.81 | IAPP (0.61) | TYRMEN1KMT2AMAPTSHBG | |
| SCHEMBL70108 | 0.79 | TYR (0.60) | TYRMEN1KMT2AMAPTSHBG | |
| SCHEMBL5202172 | 0.78 | ERCC1 (0.41) | MAPTSHBGPRKCIIAPPCYP3A4 | |
| SCHEMBL31244461 | 0.76 | TYR (0.57) | TYRMEN1KMT2AMAPTSHBG | |
| SCHEMBL8470006 | 0.76 | TYR (0.57) | TYRMEN1KMT2AMAPTSHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11224222-B2 | Synergistic compositions of dehydroacetic acid and methods for reducing yellowing in various end-user compositions | ISP INVESTMENTS LLC (US) | 2022-01-18 | — | — | US | disclosed |
| CN-107613954-B | Synergistic compositions of dehydroacetic acid and methods of reducing yellowing in various end-use compositions | ISP投资有限公司 | 2021-10-19 | — | — | CN | disclosed |
| CN-109111407-A | A kind of benzo isoxazole class compound derivatives and its application | 江苏恩华药业股份有限公司 | 2019-01-01 | — | — | CN | disclosed |
| US-20180055048-A1 | SYNERGISTIC COMPOSITIONS OF DEHYDROACETIC ACID AND METHODS FOR REDUCING YELLOWING IN VARIOUS END-USER COMPOSITIONS | ISP INVESTMENTS LLC (US) | 2018-03-01 | — | — | US | disclosed |
| EP-3273937-A1 | SYNERGISTIC COMPOSITIONS OF DEHYDROACETIC ACID AND METHODS FOR REDUCING YELLOWING IN VARIOUS END-USER COMPOSITIONS | ISP Investments Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| WO-2016154511-A1 | SYNERGISTIC COMPOSITIONS OF DEHYDROACETIC ACID AND METHODS FOR REDUCING YELLOWING IN VARIOUS END-USER COMPOSITIONS | ISP INVESTMENTS INC. (US) | 2016-09-29 | — | — | WO | disclosed |
| EP-1817301-A1 | POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2007-08-15 | — | — | EP | disclosed |
| EP-1817300-A1 | POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006057860-A1 | POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2006-06-01 | — | — | WO | disclosed |
| WO-2006057870-A1 | POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180055048-A1 | SYNERGISTIC COMPOSITIONS OF DEHYDROACETIC ACID AND METHODS FOR REDUCING YELLOWING IN VARIOUS END-USER COMPOSITIONS | ALAD, SCD, DHCR7 | TYR 611/4885MEN1 3671/4885KMT2A 2387/4885 |
| US-11224222-B2 | Synergistic compositions of dehydroacetic acid and methods for reducing yellowing in various end-user compositions | ALAD, SCD, DHCR7 | TYR 611/4885MEN1 3671/4885KMT2A 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.